RTW Venture Fund Ltd

Research RTW Venture Fund Ltd (RTW) on Bullrun: market cap USD 786.50M, P/E 3.9. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 786.50M; P/E is 3.9.

Peer valuation comparison

Latest P/E is 3.87x versus a Financial Services sector median of 14x (72.3% below).

Latest P/E is 3.87x versus a United States median of 25.02x (84.5% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 250.89MUSD 245.19MUSD 105.25Mn/a0.63USD 5.99Mn/aUSD 865.22M
FY2024USD 38.73MUSD 34.18M-USD 124.34Mn/a0.11USD 5.36Mn/aUSD 632.64M
FY2023USD 86.30MUSD 83.19MUSD 33.54Mn/a0.36USD 2.72Mn/aUSD 429.02M
FY2022-USD 36.51M-USD 39.44MUSD 10.35Mn/a-0.17USD 6.97Mn/aUSD 347.92M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-07-09USD 786.50M3.9n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 USD.

About RTW Venture Fund Ltd

RTW Biotech Opportunities Ltd is a venture capital fund. The fund specializes in directly investing and early-stage. The fund specializes in identifying transformative assets with high growth potential across the life sciences, biopharmaceutical and medical technology sectors. The fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

Related stock research

Other Financial Services stocks

Frequently asked questions

What is RTW Venture Fund Ltd's market cap?

RTW Venture Fund Ltd's market capitalization is USD 786.50M.

What is RTW Venture Fund Ltd's P/E ratio?

RTW Venture Fund Ltd's price-to-earnings (P/E) ratio is 3.9.

What does RTW Venture Fund Ltd do?

RTW Biotech Opportunities Ltd is a venture capital fund. The fund specializes in directly investing and early-stage. The fund specializes in identifying transformative assets with high growth potential across the life sciences, biopharmaceutical and medical technology sectors. The fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.